In a Nov. 1 blog post, software engineer Nicolas Chagnet argues that Gleam pairs a simple functional syntax with the Erlang ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.

Recursion Pharmaceuticals is using AI to improve how we develop drugs. The company has partnered with several major corporations in this quest. The biotech has yet to show meaningful results from its ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

The deal to merge into Recursion caps off a tumultuous year for Exscientia, which uses AI to aid drug discovery. (asbe/iStock/Getty Images Plus) After a year defined by pipeline cuts, the departure of ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Chipmaker Nvidia will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm's artificial intelligence models for drug discovery. Salt Lake City, Utah-based ...

Recursion, whose advisers include AI pioneer Yoshua Bengio, will use its biological and chemical datasets exceeding 23,000 terabytes to train AI models on Nvidia's cloud platform. Sign up here. Nvidia ...